Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study

• DOI: 10.1016/j.jhepr.2024.101191
• Publication Date: 2024-08-23T10:38:13Z
• Authors: Valeria Perez-Cam...; Pierre-Emmanuel R...; Thomas Marjot; Michael Praktiknjo; Edilmar Alvarado-...; Laura Turco; Luis Ibáñez-Saman...; Carlos González-A...; Ángela Puente; Elba Llop; Macarena Simón-Ta...; Carmen Álvarez-Na...; Thomas Reiberger; Xavier Verhelst; Luis Tellez; Johanna Birte Ber...; Lara Orts; Giuseppe Grassi; Anna Baiges; Payance Audrey; Jonel Trebicka; Candid Villanueva; Maria Cristina Mo...; Sam Murray; Georgina Meacham; Marc Luetgehetmann; Julian Schulze zu...; Juan-Carlos Garcí...; Eleanor Barnes; Aurélie Plessier; Virginia Hernánde...
• Keywords: 2019-20 coronavirus outbreak; Betacoronavirus; Coronavirus

Patients with vascular liver diseases (VLD) are at higher risk of both severe courses COVID-19 disease and thromboembolic events. The impact SARS-CoV-2 vaccination in patients VLD has not been described represents the aim our study. International, multicenter, prospective observational study analyzing incidence infection after vaccination, severity side effects, occurrence events hepatic decompensation. In a subgroup patients, humoral cellular responses to were also analyzed. A total 898 from 14 European centers - part VALDIG network included, 872 (97.1%) received two vaccine doses (fully vaccinated), 674 (75.1%) three doses. Of cohort, 151/898 had prior whom 9/151 (5.9%) re-infected. 747/898 who previously infected, 11.2% (84/747) diagnosed during period. Two infected required intensive care unit admission was fatal fully vaccinated patients. Adverse effects reported around 40% local being most frequent. During period, 31 (3.5%) 21 (2.3%) decompensations. No cases vaccine-induced thrombocytopenia reported. Vaccine immunogenicity assessed 36 patients; seroconversion reached 100% IFNy T-cell significantly increased post mRNA-1273 seem have preserved immune response which appears be safe effective preventing infection. Our cannot definitively establish direct link between thrombotic events, though contribution as cofactor remains elucidated. disease. potential risks associated against this need thorough investigation. research enhances understanding VLD, highlighting its good tolerability. Moreover, appear providing protection no